How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vaccines Delivery Market
- By Delivery Method: Syringes and Needles, Jet Injectors, Microneedle Patches, Oral Delivery Systems, Nasal Sprays
- By End User: Hospitals, Clinics, Pharmacies, Government Immunization Programs, Travel Clinics
- By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
- By Packaging Type: Pre-filled Syringes, Multi-dose Vials, Single-dose Vials, Cartridges
- By Cold Chain Equipment: Refrigerators, Freezers, Cold Boxes, Temperature Monitoring Devices, Insulated Shipping Containers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Syringes and Needles leads By Delivery Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Vaccines Delivery Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Delivery Method 5
End User 5
Vaccine Type 5
Packaging Type 4
Cold Chain Equipment 5
Companies profiled
Pfizer Inc.
Moderna Inc.
GlaxoSmithKline plc
Sanofi S.A.
Johnson & Johnson
AstraZeneca plc
Merck & Co. Inc.
Bharat Biotech International Ltd.
Serum Institute of India Pvt. Ltd.
CureVac N.V.
Novavax Inc.
Sinovac Biotech Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bharat Biotech International Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Serum Institute of India Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CureVac N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Novavax Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sinovac Biotech Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sinopharm Group Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Dickinson and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →BioNTech SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,066M by 2033 · 7.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Syringes and Needles37.2
- Jet Injectors18.9
- Microneedle Patches18.3
- Oral Delivery Systems13.7
- Nasal Sprays11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,284M → $2,604M · 9.2%
Europe$894.7M → $1,700M · 8.4%
Asia Pacific$816.9M → $1,554M · 8.4%
Latin America$505.7M → $1,032M · 9.3%
Middle East and Africa$389.0M → $732.4M · 8.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.712026
7.712027
7.712028
7.742029
7.752030
7.762031
7.782032
7.782033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.13.1
- Moderna Inc.11.8
- GlaxoSmithKline plc13.2
- Sanofi S.A.13.8
- Johnson & Johnson6.7
- AstraZeneca plc13.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Delivery Method11.0%
End User25.5%
Vaccine Type22.9%
Packaging Type31.3%
Cold Chain Equipment9.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.2
- Europe22.3
- Asia Pacific20.4
- Latin America13.5
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 94 | 92 | 77 | 75 | 92 | 92 | 87 |
| Moderna Inc. | 71 | 68 | 87 | 83 | 74 | 89 | 79 |
| GlaxoSmithKline plc | 72 | 85 | 83 | 73 | 62 | 82 | 76 |
| Sanofi S.A. | 73 | 77 | 69 | 66 | 82 | 74 | 74 |
| Johnson & Johnson | 66 | 76 | 74 | 70 | 63 | 55 | 67 |
| AstraZeneca plc | 59 | 51 | 71 | 66 | 54 | 51 | 59 |
| Merck & Co. Inc. | 59 | 56 | 48 | 56 | 46 | 59 | 54 |
| Bharat Biotech International Ltd. | 51 | 40 | 40 | 53 | 51 | 40 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Moderna Inc.
- GlaxoSmithKline plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Moderna Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| GlaxoSmithKline plc | ◐ | ✓ | ✓ | ◐ | − | ✓ |
| Sanofi S.A. | − | ✓ | ◐ | ✓ | ✓ | ✓ |
| Johnson & Johnson | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| AstraZeneca plc | ◐ | − | ◐ | ◐ | ◐ | − |
| Merck & Co. Inc. | − | − | ◐ | ◐ | − | − |
| Bharat Biotech International Ltd. | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.87
2Moderna Inc.79
3GlaxoSmithKline plc76
4Sanofi S.A.74
5Johnson & Johnson67
6AstraZeneca plc59
7Merck & Co. Inc.54
8Bharat Biotech International Ltd.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Moderna Inc.
Challenger3
Strong scale, closing on the leaders.
GlaxoSmithKline plcSanofi S.A.Johnson & Johnson
Contender1
Focused players with pockets of strength.
AstraZeneca plc
Niche2
Specialists in a single segment or region.
Merck & Co. Inc.Bharat Biotech International Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Delivery Method in North America, then scale across Vaccines Delivery Market — a $78M beachhead inside a $1.20B market.
Beachhead (SOM)$78Mobtainable near-term
Serviceable (SAM)$475Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Syringes and Needles
Best fit — highest urgency & budget in Delivery Method.
Economic buyer75 fit
Jet Injectors
Strong fit — clear ROI and a fast path to value.
End user65 fit
Microneedle Patches
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Delivery Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Vaccine Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Delivery Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vaccines Delivery Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation11%
Closed-won6%
$13.1KCAC
$64KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Vaccines Delivery Market is a durable-growth opportunity — $3.07B by 2033, compounding at 6.9%.
TAM · 2025$1.80Btoday
TAM · 2033$3.07Bforecast
CAGR6.9%2027–2033
Cumulative$21.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.07BTotal addressable market
SAM$1.27BServiceable available market
SOM$238MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.9% CAGR
Demand compounds through 2033, outpacing GDP across Delivery Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Delivery Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.07BLarge & growingTAM by 2033 at 6.9% CAGR
$1.27BServiceable nowreachable with today’s model
$238MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.40BBear4.5% CAGR
$3.07BBase6.9% CAGR
$3.93BBull9.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Vaccines Delivery Market — a $7.28B market by 2033. Plan: grow share from 5.1% to 11.1%.
Market size · 2033$7.28Btotal addressable
Market CAGR7.9%2027–2033
Target share11.1%from 5.1% today
Revenue ambition$808Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.1% | 11.1% | At risk |
| Revenue | $400M | $808M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.4% | 44.7% | At risk |
| Customer retention | 89.8% | 94.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Delivery Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Delivery Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $93M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Delivery Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Vaccines Delivery Market conversation — a $6.11B market you can size, segment and defend in minutes.
Market size · 2033$6.11Btotal opportunity
Growth8.0%CAGR to 2033
Addressable buyers1,195+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Delivery Method
Goal Grow share in Delivery Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 4 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Pfizer Inc.Moderna Inc.GlaxoSmithKline plcSanofi S.A.Johnson & JohnsonAstraZeneca plcMerck & Co. Inc.Bharat Biotech International Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vaccines Delivery Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Vaccines Delivery Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Vaccines and Parasiticides for Pet Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportVaccines and Drugs for Duck Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportVaccines and Drugs for Chicken Market
Vaccines and Drugs for Chicken Market is valued at USD 3.12 Billion in 2025 and is expected to …
$3.1B market · 2025 base year
View reportVaccines Administered Orally Market
Market size, share, segmentation and regional forecast.
$880M market · 2025 base year
View reportVaccine Rubber Stopper Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportVaccine Refrigerated Warehousing Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportVaccine Refrigerant Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportVaccine Production Equipment Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportVaccine Packaging Container Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportVaccine Nasal Spray Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportVaccine Monitoring System Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportVaccine Monitoring Kits Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.